Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma

Keiichiro Nakamura, Fernando Abarzua, Atsushi Hongo, Junichi Kodama, Yasutomo Nasu, Hiromi Kumon, Yuji Hiramatsu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are Kunitz-type serine protease inhibitors that have a broad inhibitory spectrum against serine proteases. This study examined the role of HAI-1 and HAI-2 in uterine leiomyosarcoma (LMS) patients, and in vitro. HAI-1 and HAI-2 was examined in uterine normal smooth muscle, leiomyoma and LMS specimens using immunohistochemistry. We investigated biological functions and inhibitory effects of HAI-1 and HAI-2 using uterine LMS cell line SK-LMS-1 and SKN. The expression levels of HAI-1 and HAI-2 were significantly decreased in uterine LMS specimens relative to corresponding uterine normal smooth muscle and leiomyoma specimens. Furthermore, the low HAI-1 and HAI-2 expression was a significant predictor for poor prognosis when compared with high HAI-1 and HAI-2 expression (disease-free survival rate; p=0.024 and p=0.045, overall survival rate; p=0.043 and p=0.009). HAI-1 and HAI-2 showed potential inhibitory effects that mediated cell proliferation, migration and cellular invasion which led to apoptosis and necrosis through a reduction of HGFA, matriptase and hepsin expression. These findings indicate that HAI-1 and HAI-2 may be possible tumor suppressor genes for uterine LMS and thus, both could be considered therapeutic agents for the treatment of LMS.

Original languageEnglish
Pages (from-to)605-614
Number of pages10
JournalInternational Journal of Oncology
Volume37
Issue number3
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Leiomyosarcoma
Leiomyoma
Smooth Muscle
Survival Rate
Serine Proteinase Inhibitors
Serine Proteases
HGF activator
Tumor Suppressor Genes
Disease-Free Survival
Cell Movement
Necrosis
Immunohistochemistry
Cell Proliferation
Apoptosis
Cell Line
Therapeutics

Keywords

  • HAI-1
  • HAI-2
  • Tumor suppressor gene
  • Uterine leiomyosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma. / Nakamura, Keiichiro; Abarzua, Fernando; Hongo, Atsushi; Kodama, Junichi; Nasu, Yasutomo; Kumon, Hiromi; Hiramatsu, Yuji.

In: International Journal of Oncology, Vol. 37, No. 3, 09.2010, p. 605-614.

Research output: Contribution to journalArticle

Nakamura, Keiichiro ; Abarzua, Fernando ; Hongo, Atsushi ; Kodama, Junichi ; Nasu, Yasutomo ; Kumon, Hiromi ; Hiramatsu, Yuji. / Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma. In: International Journal of Oncology. 2010 ; Vol. 37, No. 3. pp. 605-614.
@article{89bf98302eac4a3bbf7fe60a004b8857,
title = "Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma",
abstract = "Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are Kunitz-type serine protease inhibitors that have a broad inhibitory spectrum against serine proteases. This study examined the role of HAI-1 and HAI-2 in uterine leiomyosarcoma (LMS) patients, and in vitro. HAI-1 and HAI-2 was examined in uterine normal smooth muscle, leiomyoma and LMS specimens using immunohistochemistry. We investigated biological functions and inhibitory effects of HAI-1 and HAI-2 using uterine LMS cell line SK-LMS-1 and SKN. The expression levels of HAI-1 and HAI-2 were significantly decreased in uterine LMS specimens relative to corresponding uterine normal smooth muscle and leiomyoma specimens. Furthermore, the low HAI-1 and HAI-2 expression was a significant predictor for poor prognosis when compared with high HAI-1 and HAI-2 expression (disease-free survival rate; p=0.024 and p=0.045, overall survival rate; p=0.043 and p=0.009). HAI-1 and HAI-2 showed potential inhibitory effects that mediated cell proliferation, migration and cellular invasion which led to apoptosis and necrosis through a reduction of HGFA, matriptase and hepsin expression. These findings indicate that HAI-1 and HAI-2 may be possible tumor suppressor genes for uterine LMS and thus, both could be considered therapeutic agents for the treatment of LMS.",
keywords = "HAI-1, HAI-2, Tumor suppressor gene, Uterine leiomyosarcoma",
author = "Keiichiro Nakamura and Fernando Abarzua and Atsushi Hongo and Junichi Kodama and Yasutomo Nasu and Hiromi Kumon and Yuji Hiramatsu",
year = "2010",
month = "9",
doi = "10.3892/ijo-00000709",
language = "English",
volume = "37",
pages = "605--614",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma

AU - Nakamura, Keiichiro

AU - Abarzua, Fernando

AU - Hongo, Atsushi

AU - Kodama, Junichi

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

AU - Hiramatsu, Yuji

PY - 2010/9

Y1 - 2010/9

N2 - Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are Kunitz-type serine protease inhibitors that have a broad inhibitory spectrum against serine proteases. This study examined the role of HAI-1 and HAI-2 in uterine leiomyosarcoma (LMS) patients, and in vitro. HAI-1 and HAI-2 was examined in uterine normal smooth muscle, leiomyoma and LMS specimens using immunohistochemistry. We investigated biological functions and inhibitory effects of HAI-1 and HAI-2 using uterine LMS cell line SK-LMS-1 and SKN. The expression levels of HAI-1 and HAI-2 were significantly decreased in uterine LMS specimens relative to corresponding uterine normal smooth muscle and leiomyoma specimens. Furthermore, the low HAI-1 and HAI-2 expression was a significant predictor for poor prognosis when compared with high HAI-1 and HAI-2 expression (disease-free survival rate; p=0.024 and p=0.045, overall survival rate; p=0.043 and p=0.009). HAI-1 and HAI-2 showed potential inhibitory effects that mediated cell proliferation, migration and cellular invasion which led to apoptosis and necrosis through a reduction of HGFA, matriptase and hepsin expression. These findings indicate that HAI-1 and HAI-2 may be possible tumor suppressor genes for uterine LMS and thus, both could be considered therapeutic agents for the treatment of LMS.

AB - Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are Kunitz-type serine protease inhibitors that have a broad inhibitory spectrum against serine proteases. This study examined the role of HAI-1 and HAI-2 in uterine leiomyosarcoma (LMS) patients, and in vitro. HAI-1 and HAI-2 was examined in uterine normal smooth muscle, leiomyoma and LMS specimens using immunohistochemistry. We investigated biological functions and inhibitory effects of HAI-1 and HAI-2 using uterine LMS cell line SK-LMS-1 and SKN. The expression levels of HAI-1 and HAI-2 were significantly decreased in uterine LMS specimens relative to corresponding uterine normal smooth muscle and leiomyoma specimens. Furthermore, the low HAI-1 and HAI-2 expression was a significant predictor for poor prognosis when compared with high HAI-1 and HAI-2 expression (disease-free survival rate; p=0.024 and p=0.045, overall survival rate; p=0.043 and p=0.009). HAI-1 and HAI-2 showed potential inhibitory effects that mediated cell proliferation, migration and cellular invasion which led to apoptosis and necrosis through a reduction of HGFA, matriptase and hepsin expression. These findings indicate that HAI-1 and HAI-2 may be possible tumor suppressor genes for uterine LMS and thus, both could be considered therapeutic agents for the treatment of LMS.

KW - HAI-1

KW - HAI-2

KW - Tumor suppressor gene

KW - Uterine leiomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=77956519685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956519685&partnerID=8YFLogxK

U2 - 10.3892/ijo-00000709

DO - 10.3892/ijo-00000709

M3 - Article

VL - 37

SP - 605

EP - 614

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -